171 related articles for article (PubMed ID: 34779495)
1. Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
Tak E; Kim M; Cho Y; Choi S; Kim J; Han B; Kim HD; Jang CS; Kim JE; Hong YS; Kim SY; Kim TW
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34779495
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of
Georgiou A; Stewart A; Cunningham D; Banerji U; Whittaker SR
Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
[TBL] [Abstract][Full Text] [Related]
3. SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
Mei Z; Shao YW; Lin P; Cai X; Wang B; Ding Y; Ma X; Wu X; Xia Y; Zhu D; Shu Y; Fu Z; Gu Y
BMC Cancer; 2018 Apr; 18(1):479. PubMed ID: 29703253
[TBL] [Abstract][Full Text] [Related]
4. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
5. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
9. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
[TBL] [Abstract][Full Text] [Related]
10. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
Arai H; Elliott A; Millstein J; Xiu J; Ou FS; Innocenti F; Wang J; Battaglin F; Jayachandran P; Kawanishi N; Soni S; Zhang W; Sohal D; Goldberg RM; Hall MJ; Scott AJ; Khushman M; Hwang JJ; Lou E; Weinberg BA; Lockhart AC; Shields AF; Abraham JP; Magee D; Stafford P; Zhang J; Venook AP; Korn WM; Lenz HJ
Oncogene; 2022 Jan; 41(2):260-267. PubMed ID: 34728807
[TBL] [Abstract][Full Text] [Related]
11. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.
Dahan L; Sadok A; Formento JL; Seitz JF; Kovacic H
Br J Pharmacol; 2009 Sep; 158(2):610-20. PubMed ID: 19732064
[TBL] [Abstract][Full Text] [Related]
13. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
Arena S; Bellosillo B; Siravegna G; Martínez A; Cañadas I; Lazzari L; Ferruz N; Russo M; Misale S; González I; Iglesias M; Gavilan E; Corti G; Hobor S; Crisafulli G; Salido M; Sánchez J; Dalmases A; Bellmunt J; De Fabritiis G; Rovira A; Di Nicolantonio F; Albanell J; Bardelli A; Montagut C
Clin Cancer Res; 2015 May; 21(9):2157-66. PubMed ID: 25623215
[TBL] [Abstract][Full Text] [Related]
14. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
15. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
16. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
17. Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.
Kundu S; Ali MA; Handin N; Padhan N; Larsson J; Karoutsou M; Ban K; Wiśniewski JR; Artursson P; He L; Hellström M; Sjöblom T
Genome Med; 2018 Jan; 10(1):2. PubMed ID: 29301589
[TBL] [Abstract][Full Text] [Related]
18. PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis.
Pan R; Dai J; Liang W; Wang H; Ye L; Ye S; Lin Z; Huang S; Xiong Y; Zhang L; Lu L; Wang O; Shen X; Liao W; Lu X
Cell Death Dis; 2023 Jun; 14(6):373. PubMed ID: 37355626
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
Sangha N; Wu R; Kuick R; Powers S; Mu D; Fiander D; Yuen K; Katabuchi H; Tashiro H; Fearon ER; Cho KR
Neoplasia; 2008 Dec; 10(12):1362-72, following 1372. PubMed ID: 19048115
[TBL] [Abstract][Full Text] [Related]
20. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]